Abstract
The true value of nanotechnology lies in its potential to improve the
solubility and enhance the efficiency of product delivery. It has been
successfully applied to the commercialisation of more than 30 drugs.
Regulators have published numerous white papers on the topic and established
Task Forces to monitor the progress and application of this technology
although there are presently no regulations specific to nanomedicine or
nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms
emerge to address the industry' s need for therapeutic, bioavailable and less
toxic products, this market is expected to grow significantly over the next
decade. Proof of concept data with novel compounds is accumulating and new
formulations of old chemotherapeutic drugs offer the promise to revolutionise
cancer therapies.
The potential of future applications:
- Tissue specific delivery - targeting the delivery of small and macro
molecules across biological membranes such as the blood brain barrier for CNS
drugs;
- Gene and vaccine delivery - non-viral delivery of genetic materials in
nanohydrogels and nanocarriers with a high degree of efficiency and expression;
- Controlled-release devices - design of new nanoporous, bioerodible
membranes;
- Increased biocompatibility - design of artificial surfaces engineering
for medical and dental implants to by-pass unwanted inflammatory response;
- Improved drug bioavailability and solubility - through the engineering
of drugs and reagents by nanostructuring;
- Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for
the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion.
The market will mature as the number of marketed nano-enabled products
doubles and second generation nanomedicines begin to emerge. These agents
will address areas of high unmet clinical need and result in the formulation
of approved and novel drugs which are safer, less toxic and more efficacious
than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly
US$2.9 billion and establish nanotechnology as an important tool in the
industry' s delivery armoury. A range of proprietary delivery platforms will
utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles
to target a number of therapy areas such as CNS disorders, oncology and
infectious diseases.
This report is part of a major new 4-volume strategic analysis
- VOLUME I: CONTROLLED- RELEASE
- VOLUME II: NANOTECHNOLOGY
- VOLUME III: NUCLEIC ACID DELIVERY
- VOLUME IV: TARGETED DELIVERY
| 
View Cart
